Cargando…

Comparative biodistribution analysis across four different (89)Zr-monoclonal antibody tracers—The first step towards an imaging warehouse

Rationale: Knowledge on monoclonal antibody biodistribution in healthy tissues in humans can support clinical drug development. Molecular imaging with positron emission tomography (PET) can yield information in this setting. However, recent imaging studies have analyzed the behavior of single antibo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bensch, Frederike, Smeenk, Michaël M., van Es, Suzanne C., de Jong, Johan R., Schröder, Carolina P., Oosting, Sjoukje F., Lub-de Hooge, Marjolijn N., Menke-van der Houven van Oordt, C. Willemien, Brouwers, Adrienne H., Boellaard, Ronald, de Vries, Elisabeth G.E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6134927/ https://www.ncbi.nlm.nih.gov/pubmed/30214621 http://dx.doi.org/10.7150/thno.26370

Ejemplares similares

(89)Zr-pembrolizumab biodistribution is influenced by PD-1-mediated uptake in lymphoid organs
por: van der Veen, Elly L, et al.
Publicado: (2020)

Interobserver reproducibility of tumor uptake quantification with (89)Zr-immuno-PET: a multicenter analysis
por: Jauw, Yvonne W. S., et al.
Publicado: (2019)

Potential and pitfalls of (89)Zr-immuno-PET to assess target status: (89)Zr-trastuzumab as an example
por: Huisman, Marc C., et al.
Publicado: (2021)

Optimal imaging time points considering accuracy and precision of Patlak linearization for (89)Zr-immuno-PET: a simulation study
por: Wijngaarden, Jessica E., et al.
Publicado: (2022)

Extracellular domain shedding influences specific tumor uptake and organ distribution of the EGFR PET tracer (89)Zr-imgatuzumab
por: Pool, Martin, et al.
Publicado: (2016)

(89)Zr-immuno-PET using the anti-LAG-3 tracer [(89)Zr]Zr-BI 754111: demonstrating target specific binding in NSCLC and HNSCC
por: Miedema, Iris H.C., et al.
Publicado: (2023)

(89)Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up
por: Bensch, Frederike, et al.
Publicado: (2018)

Noise sensitivity of (89)Zr-Immuno-PET radiomics based on count-reduced clinical images
por: Somasundaram, Ananthi, et al.
Publicado: (2022)

(89)Zr-cetuximab PET imaging in patients with advanced colorectal cancer
por: Menke-van der Houven van Oordt, Catharina Willemien, et al.
Publicado: (2015)

(89)Zr-Onartuzumab PET imaging of c-MET receptor dynamics
por: Pool, Martin, et al.
Publicado: (2017)

Molecular imaging to support cancer immunotherapy
por: van de Donk, Pim P, et al.
Publicado: (2022)

Noise-Induced Variability of Immuno-PET with Zirconium-89-Labeled Antibodies: an Analysis Based on Count-Reduced Clinical Images
por: Jauw, Yvonne W. S., et al.
Publicado: (2018)

3D Convolutional Neural Network-Based Denoising of Low-Count Whole-Body (18)F-Fluorodeoxyglucose and (89)Zr-Rituximab PET Scans
por: de Vries, Bart M., et al.
Publicado: (2022)

Validation of simplified uptake measures against dynamic Patlak K(i) for quantification of lesional (89)Zr-Immuno-PET antibody uptake
por: Wijngaarden, Jessica E., et al.
Publicado: (2023)

(89)Zr-mAb3481 PET for HER3 tumor status assessment during lapatinib treatment
por: Pool, Martin, et al.
Publicado: (2017)

Immuno-Positron Emission Tomography with Zirconium-89-Labeled Monoclonal Antibodies in Oncology: What Can We Learn from Initial Clinical Trials?
por: Jauw, Yvonne W. S., et al.
Publicado: (2016)

Explainable artificial intelligence (XAI) in radiology and nuclear medicine: a literature review
por: de Vries, Bart M., et al.
Publicado: (2023)

[(89)Zr]Zr-DFO-girentuximab and [(18)F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma
por: Verhoeff, Sarah R., et al.
Publicado: (2023)

Molecular imaging biomarkers for immune checkpoint inhibitor therapy
por: van de Donk, Pim P, et al.
Publicado: (2020)

[(89)Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer
por: van Helden, E. J., et al.
Publicado: (2019)

Early (18)F-FDG PET/CT Evaluation Shows Heterogeneous Metabolic Responses to Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer
por: van Helden, Erik J., et al.
Publicado: (2016)

Successful Trastuzumab-Deruxtecan Rechallenge After Interstitial Lung Disease: A Case Report
por: de Weger, Vincent A., et al.
Publicado: (2023)

Treatment with somatostatin analogues and PRRT in metastatic middle ear adenoma with neuroendocrine features
por: Lima Ferreira, Joana, et al.
Publicado: (2021)

Methylated Cell-Free DNA Sequencing (MeD-seq) of LpnPI Digested Fragments to Identify Early Progression in Metastatic Renal Cell Carcinoma Patients on Watchful Waiting
por: Bos, Manouk K., et al.
Publicado: (2023)

Hepatosplenic Candidiasis Without Prior Documented Candidemia: An Underrecognized Diagnosis?
por: van Prehn, Joffrey, et al.
Publicado: (2017)

(89)Zr-PET imaging to predict tumor uptake of (177)Lu-NNV003 anti-CD37 radioimmunotherapy in mouse models of B cell lymphoma
por: Giesen, Danique, et al.
Publicado: (2022)

Manual Versus Artificial Intelligence-Based Segmentations as a Pre-processing Step in Whole-body PET Dosimetry Calculations
por: van Sluis, Joyce, et al.
Publicado: (2022)

Immuno-PET Imaging to Assess Target Engagement: Experience from (89)Zr-Anti-HER3 mAb (GSK2849330) in Patients with Solid Tumors
por: Menke-van der Houven van Oordt, C. Willemien, et al.
Publicado: (2019)

Imaging the distribution of an antibody-drug conjugate constituent targeting mesothelin with (89)Zr and IRDye 800CW in mice bearing human pancreatic tumor xenografts
por: ter Weele, Eva J., et al.
Publicado: (2015)

Systemic Therapy for Patients with HER2-Positive Breast Cancer and Brain Metastases: A Systematic Review and Meta-Analysis
por: Werter, Inge M., et al.
Publicado: (2022)

(89)Zr-labeled CEA-targeted IL-2 variant immunocytokine in patients with solid tumors: CEA-mediated tumor accumulation and role of IL-2 receptor-binding
por: van Brummelen, Emilie M.J., et al.
Publicado: (2018)

PET/CT Imaging of (89)Zr-N-sucDf-Pembrolizumab in Healthy Cynomolgus Monkeys
por: Li, Wenping, et al.
Publicado: (2020)

The Mkk(3/6)-p38–Signaling Cascade Alters the Subcellular Distribution of Hnrnp A1 and Modulates Alternative Splicing Regulation
por: van der Houven van Oordt, Willemien, et al.
Publicado: (2000)

Lesion detection by [(89)Zr]Zr-DFO-girentuximab and [(18)F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma
por: Verhoeff, Sarah R., et al.
Publicado: (2019)

Pharmacokinetic Boosting of Kinase Inhibitors
por: Westra, Niels, et al.
Publicado: (2023)

[(18)F]FES uptake in the pituitary gland and white matter of the brain
por: Iqbal, R., et al.
Publicado: (2021)

Harnessing Integrative Omics to Facilitate Molecular Imaging of the Human Epidermal Growth Factor Receptor Family for Precision Medicine
por: Pool, Martin, et al.
Publicado: (2017)

Diagnostic Performance of [(18)F]FDG PET in Staging Grade 1–2, Estrogen Receptor Positive Breast Cancer
por: Iqbal, Ramsha, et al.
Publicado: (2021)

Performance of nanoScan PET/CT and PET/MR for quantitative imaging of (18)F and (89)Zr as compared with ex vivo biodistribution in tumor-bearing mice
por: Chomet, Marion, et al.
Publicado: (2021)

Biodistribution of a Mitochondrial Metabolic Tracer, [(18)F]F-AraG, in Healthy Volunteers
por: Levi, Jelena, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_m4bfcj643mdmhjhrrhs81fkra6